Journal profile · Endocrinology & Metabolism
Journal of Inherited Metabolic Disease
ISSN 0141-8955 · eISSN 1573-2665 · Springer Netherlands · NETHERLANDS · Bimonthly · Founded 1978
Journal of Inherited Metabolic Disease: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.7; hybrid open access; APC about USD 3,470; median 114 days to acceptance (97 articles, last 24 months); community-reported acceptance: moderate; 153 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Inherited Metabolic Disease is published by Springer Netherlands and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Metabolism and Genetic Disorders, Lysosomal Storage Disorders Research and Mitochondrial Function and Pathology, together about 42.5% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Inherited Metabolic Disease (JIMD) is the official journal of the Society for the Study of Inborn Errors of Metabolism (SSIEM). By enhancing communication between workers in the field throughout the world, the JIMD aims to improve the management and understanding of inherited metabolic disorders. It publishes results of original research and new or important observations pertaining to any aspect of inherited metabolic disease in humans and higher animals. This includes clinical (medical, dental and veterinary), biochemical, genetic (including cytogenetic, molecular and population genetic), experimental (including cell biological), methodological, theoretical, epidemiological, ethical and counselling aspects. The JIMD also reviews important new developments or controversial issues relating to metabolic disorders and publishes reviews and short reports arising from the Society's annual symposia. A distinction is made between peer-reviewed scientific material that is selected because of its significance for other professionals in the field and non-peer- reviewed material that aims to be important, controversial, interesting or entertaining (“Extras”).
From the journal's Aims & Scope
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief Matthias R. BaumgartnerPublisher website
Editorial board by country: none in mainland China; most named United States 9, United Kingdom 7, Germany 7, Netherlands 7, Switzerland 6 (53 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Metabolism and Genetic DisordersBiochemistry, Genetics and Molecular Biology27%
- Lysosomal Storage Disorders ResearchMedicine8.3%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology7.2%
- Amino Acid Enzymes and MetabolismBiochemistry, Genetics and Molecular Biology6.4%
- Biochemical and Molecular ResearchBiochemistry, Genetics and Molecular Biology6.4%
- Folate and B Vitamins ResearchMedicine6.3%
- Neonatal Health and BiochemistryMedicine4.8%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedCASCurrent ContentsPublisher website
Other: EBSCO, Biological Abstracts (Clarivate Analytics), Biomedical Reference Collection (EBSCO Publishing), BIOSIS Previews (Clarivate Analytics)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.7LetPub ·
- Impact factor (publisher)
- 3.8Publisher website ·
- Impact factor (publisher) 2025
- 3.8Publisher website ·
- CiteScore 2026-06
- 6.4LetPub ·
- CiteScore (publisher)
- 6.4Publisher website ·
- CiteScore (publisher) 2025
- 6.4Publisher website ·
- SJR 2026-06
- 1.4LetPub ·
- SNIP 2026-06
- 1.59LetPub ·
- h-index
- 91LetPub ·
- h-index
- 153OpenAlex ·
- i10-index
- 3,994OpenAlex ·
- 2-year mean citedness
- 3.86OpenAlex ·
- Self-citation rate
- 10.5%LetPub ·
- Share of gold OA articles
- 67.98%LetPub ·
Volume
- Articles per year
- 123LetPub ·
- Articles per year (publisher) 2025
- 131Publisher website ·
- Downloads per year (publisher) 2025
- 627,239Publisher website ·
Articles by year OpenAlex count · 7,026 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 128 | 102 | 70 |
| 2025 | 153 | 128 | 563 |
| 2024 | 140 | 120 | 990 |
| 2023 | 124 | 104 | 1,405 |
| 2022 | 123 | 84 | 1,583 |
| 2021 | 116 | 72 | 2,431 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
114 daysMedian, submission to acceptance · P25–P75 76 days – 161 days
- Acceptance to online
- median 21 days (98 articles)
- Submission to online
- median 132 days
- Sample
- 97 articles with submission and acceptance dates (305 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Acceptance rate (publisher)
- 24%Publisher website ·
- Acceptance rate (publisher) 2025
- 24%Publisher website ·
- Submission to first decision
- 5 daysPublisher website ·
- Submission to first decision 2025
- 5 daysPublisher website ·
- Submission to acceptance 2025
- 105 daysPublisher website ·
- Acceptance to publication 2025
- 19 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,470 / EUR 2,890 / GBP 2,310 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Cover letter
- Required
Article types accepted5
- editorialsEditorials The JIMD invites communicating editors and reviewers of articles that have been accepted for publication in the JIMD to provide an editorial that pla…Length not stated
- guidelinesGuidelines: Studies providing a comprehensive, representative analysis of the clinical features, treatment and outcome of inborn errors of metabolism.Length not stated
- images in metabolic medicineImages in Metabolic Medicine The Editors will consider clear and interesting clinical pictures or other types of images (e.g. laboratory results or observations…Length not stated
- original articlesOriginal Articles: Important manuscripts that may be expected to influence or change clinical or research practice with regard to inherited metabolic disorders.Length not stated
- reviewsReviews: Concise summaries of metabolic pathways, specific disorders, methods, treatment options etc.Length not stated
Policy excerpts from the journal's websiteAI use, Data availability, Open access, Preprints
- AI use Artificial Intelligence Generated Content
Authors must disclose any use of generative AI in scientific writing at submission. This applies only to the writing process, not to AI used for data analysis or research. Generative AI may only be used to improve readability and language. Authors must review and edit all AI-generated content, as it may be inaccurate, incomplete, or biased. Authors remain fully responsible for the manuscript. AI t…
Source ↗Publisher website ·- Data availability Data Sharing Policies
Data sharing policy Model summary
JIMD recognizes the many benefits of archiving research data. We expect you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Princ…
Source ↗Publisher website ·- Open access Open Access
Open access is available to authors of primary research articles who wish to make their article freely accessible to all, or whose funding agency requires grantees to archive the final version of their article. With open access the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley O…
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy Model summary
This journal will consider for peer review articles previously available as preprints on non-commercial servers such as arXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, etc. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication. If your manuscript is availab…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Netherlands
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1978
- ISSN
- 0141-8955
- Electronic ISSN
- 1573-2665
- Society / sponsor
- Society for the Study of Inborn Errors of Metabolism
- Latest issue on the website
- Volume 49, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Inherited Metabolic Disease
What CAS zone is Journal of Inherited Metabolic Disease in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Inherited Metabolic Disease is in Zone 2 of Medicine, and in Zone 2 of the minor category Endocrinology & Metabolism / Genetics & Heredity / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Inherited Metabolic Disease?
The latest impact factor listed by LetPub is 3.7; CiteScore 6.4, h-index 153.
How long does peer review take at Journal of Inherited Metabolic Disease?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 114 days (interquartile range 76–161 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate”; the journal's website gives an acceptance rate of 24% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Inherited Metabolic Disease based?
Of the 53 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (9), United Kingdom (7) and Germany (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Inherited Metabolic Disease?
According to LetPub and DOAJ records, Journal of Inherited Metabolic Disease is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, CAS and Current Contents; that list has not been checked against each database.
Is Journal of Inherited Metabolic Disease open access, and what is the APC?
Journal of Inherited Metabolic Disease is a hybrid journal. For open-access publication: APC about USD 3,470.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .